A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma

• Main Authors: Peiyao Lu (Author), Weiting Liang (Author), Jiahao Li (Author), Yanming Hong (Author), Zhuojia Chen (Author), Tao Liu (Author), Pei Dong (Author), Hongbing Huang (Author), Tiantian Zhang (Author), Jie Jiang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundCompared with the standard of care with sunitinib, avelumab plus axitinib can increase progression-free survival in the first-line of advanced renal cell carcinoma (RCC), but the economic effect of the treatment is unknown. The purpose of the research was to evaluate the cost-effectiveness...